Investor Presentaiton

Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars aflibercept - VEGF inhibitor NCT04864834 Mylight (CSOK583A12301) Indication Ophthalmology indication (as originator) Phase Phase 3 Patients 460 Primary Outcome Measures Arms Intervention Target Patients Best-corrected visual acuity (BCVA) will be assessed using the ETDRS testing charts at an initial distance of 4 meters. The change from baseline in BCVA in letters is defined as difference between BCVA score between week 8 and baseline Arm 1 Biological: SOK583A1 (40 mg/mL) Arm 2 Biological: Eylea EU (40 mg/mL) Patients with neovascular age-related macular degeneration Read-out 2023 Milestone(s) Publication tbd 105 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation